menu
    • menu
    [{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Caelum Biosciences

    Menu

    Caelum Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amylo...

                            Details : An e-poster featuring the first data from a new arm of the study demonstrated that CAEL-101 administered in combination with cyclophosphamide-bortezomib-dexamethasone (CyBorD) plus daratumumab was generally safe and well-tolerated in the first four weeks...

                            Product Name : CAEL-101

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 06, 2021

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Astra Zeneca to Fully Acquire Caelum Biosciences

                            Details : AstraZeneca will accelerate ongoing Phase III clinical development of CAEL-101, a potential first-in-class medicine which is being evaluated in the Cardiac Amyloid Reaching for Extended Survival Phase III clinical programme in combination with standard-o...

                            Product Name : CAEL-101

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 29, 2021

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

                            Details : Caelum was acquired by AstraZeneca pursuant to the developing and commercializing biopharmaceutical products and product candidates cost-effectively including Caelum’s lead asset, CAEL-101, is a novel antibody for the treatment of patients with light c...

                            Product Name : CAEL-101

                            Product Type : Antibody

                            Upfront Cash : $150.0 million

                            June 10, 2021

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Caelum Biosciences

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meet...

                            Details : Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis. Data, from Caelum, that further shows safety and tolerability of CAEL-101 and support the selection of the 1000 mg/m2 dose for the Phase 3 study wi...

                            Product Name : CAEL-101

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 11, 2020

                            Lead Product(s) : CAEL-101,Bortezomib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth